Mubritinib
编号: 16071022
Cas号: 366017-09-6
纯度: 98% by HPLC
Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials (may be discontinued since 2008). Mubritinib(TAK 165) is a potent EGFR, HER2 and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 ÂM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5. Mubritinib(TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Mubritinib(TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Mubritinib |
|---|---|
| Iupac 化学名称 | (E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole |
| 同义词 | Mubritinib; TAK 165 |
| 英文同义词 | Mubritinib; TAK 165 |
| 分子式 | C25H23F3N4O2 |
| 分子量 | 468.47093 |
| Smile | N1(N=NC=C1)CCCCC1=CC=C(OCC=2N=C(OC2)\C=C\C2=CC=C(C=C2)C(F)(F)F)C=C1 |
| InChiKey | ZTFBIUXIQYRUNT-MDWZMJQESA-N |
| InChi | InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+ |
| Cas号 | 366017-09-6 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
